RE:RE:RE:What happens if Oast does not agree?lscfa wrote: This is BS. Gagnon is assuming the merged co. can raise equity easier and at better valuations than CZO can. No damn proof this is possible.
"The transaction provides us with the additional capital and internal capabilities to fully support near-term revenue generating cosmeceutical and nutraceutical product development programs..."
That's not what Gagnon said. The merger is significantly a financing for CZO's growth plan. Gagnon said the merger provides CZO with additonal capital and internal capabilities. This is echoed by AEZS's Chair:
Carolyn Egbert, Chair of Aeterna: “Ceapro has well-established and growing commercial operations, with potential value-creating pipeline opportunities in large and growing cosmetic and consumer health markets. We believe that the new company will have the capital resources to support this ongoing growth, in addition to continuing to maximize the value of Aeterna’s existing assets, including Macimorelin.”We believe that the new company will have the capital resources to support this ongoing growth, in addition to continuing to maximize the value of Aeterna’s existing assets, including Macimorelin.”
AEZS's cash and upfront and milestone payments plus royalties from the diagnostic test will be used to drive CZO's growth. “We are thrilled with this exciting transaction to merge with Aeterna and combine two complementary companies and teams, in support of our plan to drive significant growth,” said Ronnie Miller, Chairman of Ceapro. “After careful consideration, we believe this transaction is the best way forward for Ceapro and our valued shareholders.”